GUANGJI PHARMA.(SZ:000952) Zheng Quan Zhi Xing·2025-08-29 22:42Core Viewpoint - Guangji Pharmaceutical (000952) reported a decline in total revenue for the first half of 2025, but showed improvement in net profit margins and gross profit margins compared to the previous year [1]. Financial Performance - Total revenue for the first half of 2025 was 284 million yuan, a decrease of 4.08% year-on-year [1]. - Net profit attributable to shareholders was -75.5151 million yuan, an increase of 29.19% year-on-year [1]. - In Q2 2025, total revenue was 136 million yuan, an increase of 16.83% year-on-year [1]. - Q2 2025 net profit attributable to shareholders was -39.2489 million yuan, an increase of 30.08% year-on-year [1]. Profitability Metrics - Gross margin increased to 30.38%, up 21.07% year-on-year [1]. - Net margin improved to -28.94%, an increase of 25.75% year-on-year [1]. - Total selling, administrative, and financial expenses amounted to 136 million yuan, accounting for 47.92% of revenue, a decrease of 3.61% year-on-year [1]. Key Financial Ratios - Earnings per share (EPS) was -0.22 yuan, an increase of 28.4% year-on-year [1]. - Operating cash flow per share was 0.07 yuan, a significant increase of 122.23% year-on-year [1]. - The company's net asset per share was 2.85 yuan, a decrease of 20.51% year-on-year [1]. Debt and Cash Flow - Cash and cash equivalents increased to 520 million yuan, up 23.80% year-on-year [1]. - Accounts receivable decreased to 167 million yuan, down 24.25% year-on-year [1]. - Interest-bearing debt decreased to 1.375 billion yuan, down 8.65% year-on-year [1]. Market and Product Development - The company has submitted a registration application for its human milk oligosaccharide product and is actively promoting its industrialization [4][5]. - The impact of U.S. trade policies on company orders is being monitored, with current tariffs on vitamin B2 products remaining at 20% [5].